

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6785

Title: Does antiviral therapy reduce complications of cirrhosis?

Reviewer code: 01713316

Science editor: Cui, Xue-Mei

Date sent for review: 2013-10-29 22:39

Date reviewed: 2013-12-04 00:47

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Kim et al have reviewed the benefits of antiviral agents in HBV cirrhosis. The authors have done a good job of classifying and reviewing the data in compensated, decompensated, and in ACLF. However, there are some major concerns with this paper which need to be addressed: 1. Decompensated cirrhosis: There are many studies which could also be covered. I would suggest to refer to a meta-analysis by Singal and Fontana in the APT 2011. 2. HCC is an important event in cirrhosis especially HBV infection. Authors should cover a separate section on benefits of treatment in reducing HCC incidence and may also like to refer to meta-analysis by Lok et al in J Hep 2011 and Singal et al in APT 2013. 3. Should also cover and review studies on the role of HBV treatment in prevention of reactivation